Specialty Pharma, Generics M&A Frenzy To Continue Into 2016: NomuraMani
The specialty pharmaceutical and generics M&A frenzy that continues to fuel strong sector performance is being driven by a host of factors which could continue to drive M&A activity into 2016, notes Nomura.
Shibani Malhotra and Austin Nelson of Nomura in their September 28, 2015 research note on “Equity: Americas Specialty Pharmaceuticals & Generics” believe sector consolidation will continue as the overall pharmaceutical industry witnesses an increasingly challenging macroeconomic environment.
M&A remains the driver of . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.